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Abstract 
Potentially adverse human and environmental effects due to hormone 
mimicry of environmental estrogens are a matter of current concern. 
Environmental estrogens belong to the so-called endocrine active 
compounds (EAC), which alter signalling processes of the endocrine 
system leading to a broad range of effects during foetal and postnatal 
development, puberty, adulthood, and aging. A number of synthetic 
chemicals as well as several plant-derived compounds, so-called 
phytoestrogens, are known to have weak estrogenic activity.  
The present study is part of the risk assessment of the weak 
environmental estrogens daidzein, p-tert-octylphenol, and bisphenol A. 
The isoflavone daidzein is an important phytoestrogen with respect to 
dietary exposure (soy beans and soy products). p-tert-Octylphenol and 
bisphenol A are industrial chemicals. The toxicokinetics and the 
bioavailability of these three substances in female DA/Han rats after 
oral and single intravenous application were investigated by the use of 
population models accounting for the differences in the individual 
metabolism. Furthermore, populations of pregnant and non-pregnant 
rats are compared. 
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1. Introduction 
 
Human exposure to so-called endocrine active compounds (EAC) in general 
and environmental estrogens in particular is a matter of current concern (DGPT 
1999; Degen and Bolt, 2000a; European Community, 1997). EACs may alter 
the signalling processes of the endocrine system that is responsible for the 
regulation and the coordination of physiological functions during foetal and 
postnatal development, puberty adulthood and aging. The signalling processes 
depend on concentrations of biologically active levels of hormones controlled 
by biosynthesis, metabolising enzymes, and binding proteins (Barton and 
Andersen, 1998; National Research Council, 1999). 
The particular class of EACs we are investigating are environmental estrogens, 
which have more or less similar effects as estrogens have. The estrogenic 
effects are primarily due to the binding to the same receptors although with 
much lower affinity, but may also arise by other mechanisms (Nilsson et al., 
2001 ).  
Sources of environmental estrogens are naturally occurring dietary compounds 
as well as the release of synthetic chemicals: Examples are plant-derived 
compounds, the so-called phytoestrogens, for instance daidzein and genistein 
isoflavones that are found in soy beans and soy products, and pesticides like 
DDT or industrial chemicals like alkylphenols, bisphenol A or PCBs, (Mäkelä 
et al., 1999). The present study considers the important isoflavone daidzein and 
the industrial chemicals bisphenol A, used e.g. in the production of plastic 
coatings in the food packaging industry, and p-tert-octylphenol, a model 
compound for the industrial chemical nonylphenol (technical mixture of a 
number of different isomers) that belongs to the group of alkylphenols (Certa et 
al., 1996).  
Concerns about endocrine active compounds in general and environmental 
estrogens in particular are whether effects on the hormonal regulation will lead 
to potentially adverse effects under the actual conditions of exposure.  
Observations leading to these concerns have been made in wildlife in certain 
regions with high exposure to environmental estrogens and/or anti-androgens, 
i.e. decreased fertility of alligators, fishes, and birds as well as feminisation 
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effects and demasculinization of mammals, birds and fishes (Tyler et al., 
1998).  
 
Table 1. Biological Endpoints Proposed to be associated with EACs (Barton 
and Andersen, 1998) 
Cancers (ovarian, breast, testicular) Altered estrous or menstrual cycling 
Transplacental carcinogenesis Steroid receptor binding or inhibition 
Decreased sperm count and motility Altered hormone levels 
Malformations of female reproductive 
tract and male urogenital tract 
Altered cell proliferation and cell 
differentiation 
Increased ectopic pregnancies Altered behaviour 
Decreased reproductive success  Hyperactivity 
Decreased weights of uterus or testes Degraded immune function 
 Imposex/ hermaphroditism 
 
At the same time, beneficial effects of dietary and pharmaceutical estrogen 
mimetic compounds are a major focus in medicine (Setchell and Cassidy, 
1999).   
Sources of exposure to synthetic compounds are mainly food and drinking 
water except for pharmaceutical xenoestrogens. Human exposure to phyto-
estrogens depends much on dietary habits, as the main sources are soybeans 
and soy products. So in Japan, for instance, the consumption of soybean 
products is 30 to 50 times higher than that in Western Europe or the United 
States (Degen and Bolt, 2000b; Degen et al., 2002a).  
Risk assessment for environmental estrogens needs to consider the following 
aspects:  
• Aside from synthetic xenoestrogens humans are mainly exposed to 
environmental estrogens of natural origin (phytoestrogens). 
•  A given compound may have agonistic (estrogenic) or anti-agonistic 
(anti-estrogenic) effects depending on the dose, the target organ and the 
endocrine state of the whole organism (Mäkelä et al., 1999).  
• Endocrine/receptor-mediated effects are not automatically adverse 
effects. 
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• Exogenous exposure to environmental estrogens has to be considered 
on the background level of endogenous estrogens.  
In assessing the risk of synthetic estrogens it is important to take the exposure 
to phytoestrogens into account along with information on toxicodynamics 
(receptor affinity potency), and toxicokinetics (Bolt et al., 2001; Bolt and 
Degen, 2002; Degen et al., 2002c).  
Therefore the present study aims to investigate the toxicokinetics and oral 
bioavailability of industrial and naturally occurring estrogens.  
 
The major problem that arises with the compounds under investigation, 
daidzein, bisphenol A, and p-tert-octylphenol, are the differences in the data 
between the observed individuals; that means individual plasma concentration 
curves differ in scale and functional form from each other. This is probably due 
to differences in the uptake of the substances, particularly after oral 
administration, as well as in their metabolism. For the metabolism of these 
three compounds the so-called enterohepatic circulation seems to play an 
important role (Figure 1).  
 
 
 
 
 
 
 
 
Figure 1. Enterohepatic circulation 
 
The parent compound is conjugated with glucuronic acid in the liver, trans-
ported with the bile in the intestine. Intestinal bacterial enzymes can cleave the 
conjugate releasing the parent compound (aglycone) that can be reabsorbed and 
transported to the liver again. Even under the same experimental setting with 
genetically almost identical experimental animals this leads to great variations 
in the plasma levels of the investigated compounds.  
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Thus, the present approach suggests in this situation of few data points per 
animal with a different number of peaks (usually one or two peaks) of different 
height at equal doses at different time points to consider first the individual 
measurements and parameters of interest and to use population models to pool 
the information in the data together. For this purpose we apply linear 
hierarchical models using the information from a previous 'naïve' approach, 
where all the data were pooled together and the AUC was estimated from the 
complete data set, as prior information. The estimation of the variance and the 
population mean was performed by an EM algorithm as proposed by Dempster 
et al. (1977). Moreover data sets of pregnant and non-pregnant rats after 
intravenous application of 10 mg/kg bodyweight daidzein were compared by 
the use of the Mann-Whitney U-test.  
 
 
2. Data 
 
The present data sets arise from the following study on xenoestrogens at the 
Institut für Arbeitsphysiologie an der Universität Dortmund (IfADo).  
First, female non-pregnant DA/Han rats were given the compound of interest 
either intravenously at a low dosing level or orally at one of two dosing levels. 
The used estrogen mimetic compounds were daidzein, bisphenol A, and p-tert-
octylphenol. The plasma concentration was determined at several time-points 
per animal. Individual samples were available 3 to 7 times per animal. The 
experimental design is given in table 2. For details see Janning et al. (2000) 
and Upmeier et al. (1999; 2000). Note, that each animal is observed at a subset 
of sampling times. The real sampling times may vary across the planned ones 
but are usually recorded.  
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Table 2. Experimental design of the xenoestrogen study with non-pregnant 
DA/Han rats. The dose is given in mg/kg body weight, I is the total number of 
animals observed in that dosing group, sample times in minutes after 
application of the substance.  
Substance Application Dose I Sample times 
intravenous 10 8 1, 5, 10, 20, 40, 60, 120, 180, 
240, 360, 480, 1440, 1920, 2880 
10 7 10, 20, 30, 45, 60, 90, 120, 180, 
240, 360, 420, 480, 1440, 1920, 
2880 
daidzein 
oral 
100 7 10, 20, 30, 45, 60, 90, 120, 180, 
240, 360, 480, 1440, 1920, 2880 
intravenous 10 9 1, 5, 10, 20, 30, 40, 60, 120, 180, 
240, 360, 480, 1440, 1920, 2880 
10 3 30, 90, 180, 360, 480, 2880 bisphenol A 
oral 100 9 10, 20, 30, 45, 90, 120, 180, 240, 
360, 480, 1440, 1920, 2880 
intravenous 5 6 1, 5, 10, 20, 40, 60, 180, 360, 
1440, 2880 
50 6 10, 20, 30, 45, 60, 90, 120, 180, 
240, 360, 480, 1440, 1920, 2880 
p-tert-
octylphenol 
oral 
200 6 10, 20, 30, 45, 60, 90, 120, 180, 
240, 360, 480, 1440, 1920, 2880 
 
The second part of the study was performed with pregnant DA/Han rats. The 
isoflavone daidzein was given intravenously at a dose of 10 mg/kg bodyweight 
to totally I=21 animals. Plasma concentrations were recorded once per animal 
(see table 3), at the time of sacrifice. Rat no. 11A was excluded from the 
analysis as the observation (measured values in plasma and tissue samples) 
differed unreasonable much from the remaining data.  
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Table 3. Experimental design of the xenoestrogen study with pregnant DA/Han 
rats; j is the index of the sample time, nj is the total number of animals 
observed in that sampling group, sample times tj in minutes since application 
of the substance.  
j tj nj  
1 5 4 (5) No 11A was dropped out of the analysis 
2 10 4  
3 20 4  
4 40 4  
5 120 4  
 
 
3. Models and Methods 
 
The parameters of interest that we aim to estimate from the present study are 
the area under the concentration-time curve (AUC) and the oral bioavailability, 
which relates the AUCs of oral and intravenous application accounting, of 
course, for the doses. A standard method for estimating the AUC is the use of 
spline functions to approximate the underlying concentration-time curve from 
data point to data point and subsequent integration of the fitted functions 
(Glaser, 1985). Hence, a linear approximation is used for the partial function 
between t1 and tJ. The AUC was calculated for every individual separately and 
pooled together for every dosing group to a population mean AUC applying a 
linear hierarchical model using the information from the 'naïve' approach as 
prior information for the estimation of the population mean and its variance as 
well as for the specification of the prior distribution of the variance of the 
individual outcomes. In case of intravenous application where the individual 
differences were not so grave a three-exponential model could be fitted to the 
pooled data set in an earlier analysis. The calculation was performed applying 
an EM algorithm as proposed by Dempster et al. (1977) and Racine-Poon and 
Smith (1990) investigating the impact of different variance functions for the 
error term. The population means of the different dosing and application 
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groups were used to calculate the oral bioavailability of the respective oral 
dosing group and compound and the results were compared across the different 
approaches and variance functions.  
Finally the plasma-concentrations of daidzein in pregnant and non-pregnant 
DA/Han rats after intravenous application in two experimental designs were 
compared by the use of the Mann-Whitney U-statistic.  
 
 
3.1 Calculation of the individual AUC 
 
The calculation of the AUCi, i = 1, . . ., I, for each individual i, was performed 
as follows: 
Given the observations (tj, yj), j = 1, . . ., J, of a single individual the 
concentration-time function is approximated by the function f(t) = y, where t is 
the time since application of the chemical in minutes, y is the plasma 
concentration in ng/ml and j is the sampling occasion. The function f(t) is given 
by  
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is the lag-time and )(*0 tf  is the linear extrapolation of f1 on [0; t1[.  
We assume that f(tj) = yj, ∀ j = 1, . . ., J, and f(t0) = 0. Furthermore, we define 
the partial functions  
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within the terminal elimination phase at time Jtt ≥ . In case of 0≥′Jy , 
JJJ btatf +=)(  with 0)( 1 =+JJ tf . The time point tJ+1, where the plasma 
concentration is surely equal to 0, is chosen according to the 'knowledge' about 
the processes under investigation.  
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The parameters aj and bj, j = 1, . . ., J, are given by  
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Hence, we obtain the AUC of each individual by integrating f(t) over [t0; ∞), 
that means integrating the partial functions fj, j = 0, . . ., J, and summing up the 
partial AUCj.  
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Considering the AUC for each experimental animal separately the individual 
AUCi, i = 1, . . ., I, is denoted by  
 ∑
=
=
J
j
iji
0
AUCAUC ,        (14) 
where i is the individual and j is the index of the partial function.  
 
In case of intravenous application it was possible to apply a three-exponential 
model to estimate the AUC from the pooled data set. The concentration-time 
curve was given by  
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3.2 Oral bioavailability 
 
The parameter of interest is the oral bioavailability, which is given by  
oralsintravenou
sintravenouoral
dose oral,F doseAUC
doseAUC
⋅
⋅
= ,     (17) 
with 'AUCoral' denoting the mean AUC from the experiment with oral 
application of the respective 'doseoral' and 'AUCintravenous' and 'doseintravenous' 
denoting the respective quantities from the experiment with intravenous 
application of the chemical.  
The problem is to obtain a 'mean AUC' especially in case of oral application. 
Hence, population models are applied to cope with this difficulty.  
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3.3 Population model 
 
According to the approach of Lindley and Smith (1972) and Racine-Poon and 
Smith (1990) the following linear hierarchical model is assumed for the log-
transformed data. 
 
ln(AUC), σ²|   ln(AUCi) ~ N(ln(AUC), σ²g(ln(AUCi) ),  i = 1, . . ., I 
ln(AUCa priori), τ²|  ln(AUC)  ~ N(ln(AUCa priori), τ²) 
r, λ|   1/ σ²      ~ Ga(r, λ) 
 
AUCa priori denotes the prior information obtained by the naïve approach and 
the function g allows for a functional relationship between observations and 
variance term. Usually it is reasonable to assume that the variance is increasing 
with increasing observations. In the present analysis we choose g(x) = x² but 
investigated also other functional relationships. The variance τ² was 
determined using  
( ) 1)ln(AUC)ln(AUCˆ
1
22
−−==∑
=
Iτ
I
i
priori ai .    (18) 
The parameters r and λ of the Gamma distribution, denoted by Ga(r, λ), are 
chosen considering the features of several Gamma distributions with r and λ 
determined by  
E(1/ σ²) = r/ λ ≈ 2ˆ1 τ ,      (19) 
assuming that the individuals show a similar variation across the population 
mean as across the a priori estimate.  
 
 
3.4 EM Algorithm 
 
The estimation of the unknown population mean ln(AUC) as well as of the 
hyperparameter σ² was performed by the use of an EM-type algorithm as 
proposed by Dempster et al. (1977). This algorithm computes iteratively the 
conditional expectation of the parameter − ln(AUC), for instance − given the 
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observations and the current estimates of the hyperparameters (E-step) and the 
maximum of the posterior distribution of the hyperparameters − 2−σ , for 
instance − given the observations and the current estimates of the parameters. 
The algorithm may be used for both: estimation within a maximum likelihood 
and within a Bayesian framework. For more complex hierarchical models, i.e. 
three or four stages, see also Selinski (2001). In the present case the algorithm 
can be easily implemented by computing the lth iteration step:  
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A reasonable starting value is given by  
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3.5 Comparison of the toxicokinetics of pregnant and 
non-pregnant rats 
 
Comparing the toxicokinetics of the pregnant and non-pregnant rats after 
intravenous application of daidzein we had to take the different experimental 
design into account. Individual concentration-time curves were only available 
for the non-pregnant rats (Janning et al., 2000). In case of the pregnant animals 
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each individual was observed just one time (at sacrifice) due to a destructive 
design (Degen et al., 2002b). Furthermore samples were taken just on a subset of 
the sampling times we had for the non-pregnant rats with the last samples taken 
from the pregnant rats 120 minutes after application of daidzein instead of 
2888 minutes.  
Thus, observations from both populations were compared separately for each 
sampling time tj, j = 1, . . ., J, by the use of the Mann-Whitney U-test which is 
equal to the Wilcoxon rank sum test (see Büning and Trenkler, 1994; 
Hollander and Wolfe, 1999).   
 
 
4. Results 
 
The individual AUCi were estimated for all dosing groups and substances 
according to eqs. (6)-(14) where tJ+1 was set to 5000 if necessary. The results 
are given in tables 8-10 in the appendix. Estimates using (13) instead of (12) 
for the terminal partial AUCiJ are printed bolt. The estimation of the respective 
population means and variance σ² was performed by the use of the EM 
algorithm given by (20) and (21) where 2τˆ  and the parameters r and λ of the 
gamma distribution were determined according to (18) and (19) (see table 5). 
The function g was chosen as g(x) = x². Results for g(x) = 1, g(x) = x and 
g(x) = 2x are given in tables 11-21 in the appendix. The oral bioavailability was 
calculated according to (17) using both population means of the oral and the 
intravenous application group (F), the population mean of the oral 
administration experiment and the AUC due to the analysis with the three-
exponential function (15) and (16) (F3-exponential) and by the use of both prior 
AUCs (F3-exponential, a priori line) (see table 4).  
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Table 4. Estimates of the population means of the AUC and the bioavailability; 
the italic quantities are the estimates from the naïve (a priori) approach; i.v. 
denotes the intravenous administration route. 
substance dose, application AUC F F3-exponential 
10 mg/kg, i.v. 501423.75 — — daidzein 
a priori 501263.49 — — 
10 mg/kg, oral 45442.08 9.06 % 9.07 %  
a priori 48622.56 — 9.7 % 
100 mg/kg, oral 89884.37 1.79 % 1.79 %  
a priori 110277.97 — 2.2 % 
10 mg/kg, i.v. 858089.98 — — bisphenol A 
a priori 1128319.31 — — 
10 mg/kg, oral 173923.49 20.27 % 15.41 %  
a priori 185044.37 — 16.4 % 
100 mg/kg, oral 430303.18 5.01 % 3.81 %  
a priori 631858.81 — 5.6 % 
5 mg/kg, i.v. 129474.05 — — p-tert- 
a priori 136661.83 — — 
50 mg/kg, oral 160625.32 12.41 % 11.75 % octylphenol 
a priori 168094.05 — 12.3 % 
200 mg/kg, oral 444345.49 8.58 % 8.13 %  
a priori 459183.74 — 8.4 % 
 
 
Table 5. Estimates of τ² and σ² and chosen parameters r and λ of the gamma 
prior of 1/σ²; i.v. denotes the intravenous administration route. 
substance dose, application 2τˆ  2~σ  r λ 
daidzein 10 mg/kg, i.v. 0.25 0.19 8 2 
 10 mg/kg, oral 0.90 0.28 2 1.81 
 100 mg/kg, oral 1.59 0.49 2 3.19 
bisphenol 
A 
10 mg/kg, i.v. 2.18 0.50 1 2 
 10 mg/kg, oral 6.98 7.02 1 7 
 100 mg/kg, oral 3.90 1.00 1 4 
 15 
p-tert- 5 mg/kg, i.v. 0.99 0.57 2 2 
octylphenol 50 mg/kg, oral 0.72 0.44 3 2 
 200 mg/kg, oral 0.64 0.44 3 2 
 
Comparing the estimates from the population approach, the combined 
population and three-exponential approach and the prior estimates reveals 
minor differences for the substances daidzein and p-tert-octylphenol whereas 
these differences are much more prominent in case of bisphenol A. 
EM algorithm converged very fast (2-4 iteration steps) and was easily 
implemented even in EXCEL.  
The estimated σ² differed usually from its respective expectation (see tables 
11-21, appendix) where the specification of g seems to have a minor impact on 
the estimate except for denying a dependence of the individual variance on the 
magnitude of the observations, that means g(x) = 1.  
In case of daidzein the choice of g also seems to have a small impact on the 
estimation of the AUC and the bioavailability (tables 11-14), but, for the 
industrial chemicals bisphenol A and p-tert-octylphenol the differences 
between the estimated AUC and oral bioavailability are considerable (tables 
18-21).  
 
The impact of the choice of r and λ were investigated for the daidzein data set 
(100 mg/kg, oral administration), see tables 13-17 (appendix), and revealed a 
negligible impact on the estimates of the AUC and σ².  
 
Comparing the plasma concentration of the pregnant and non-pregnant 
DA/Han rats reveals that the plasma levels are not consistently higher or lower 
in pregnant rats over the complete duration of the experiment (see table 6).  
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Table 6. Sampling times in minutes and plasma concentration of daidzein 
(aglycone) in ng/ml in pregnant and non-pregnant DA/Han rats after i.v. 
administration of 10 mg/kg daidzein.  
Non-pregnant Pregnant  
Rat no.  time  concentration Rat no.  time  concentration 
63 1 42358     
16 2 20575       
8 5 18248 9A 5 3020 
23 5 7602 (11A 5 117880) 
71 5 10172 12A 5 1712 
     16A 5 1140 
      22A 5 875 
12 10 17033 2B 10 14780 
68 10 5057 4B 10 3290 
69 10 7592 6B 10 4240 
      14B 10 2240 
63 20 3071 36E 20 1422 
16 23 2143 37E 20 404 
     38E 20 511 
      39E 20 897 
71 40 674 7C 40 345 
23 41 390 8C 40 123 
8 44 447 10C 40 45 
      15C 40 624 
12 58 405     
68 60 511       
63 120 45 1D 120 173 
16 122 191 3D 120 359 
     5D 120 148 
      13D 120 593 
23 179 121     
71 180 105     
8 191 115     
68 240 23     
69 240 107     
12 242 93     
12 360 15     
63 360 25     
69 360 8     
71 360 108     
16 478 47     
12 480 0     
69 480 5     
71 480 72     
63 1440 0     
69 1440 11     
71 1440 106     
8 1442 0     
23 1444 27     
8 1926 0     
16 2888 37       
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The plasma concentration seems to be lower in pregnant rats that in non-preg-
nant individuals at least within the first half hour after intravenous application 
of daidzein. The Mann-Whitney U-test reveals notable differences after t = 5 
minutes (p < 0.05) and after t = 20 minutes (p < 0.1). No differences are 
detectable for t = 10, 40, and 120 minutes, respectively, (table 7) although the 
explorative analysis suggests that the plasma concentrations are higher in preg-
nant than in non-pregnant rats 120 minutes after administration of daidzein.  
 
Table 7. Results of the Mann-Whitney U-test of differences between pregnant 
and non-pregnant DA/Han rats after i.v. administration of 10 mg/kg daidzein. 
non-pregnant pregnant Mann-Whitney U-test 
rat no.  time concentration rat no.  time concentration reject H0, α =  
23 5 7602 22A 5 875 reject H0, α = 0.05 
71 5 10172 16A 5 1140   
8 5 18248 12A 5 1712   
      9A 5 3020   
68 10 5057 14B 10 2240 not reject H0 
69 10 7592 4B 10 3290 α = 0.1/ 0.05 
12 10 17033 6B 10 4240   
      2B 10 14780   
16 23 2143 37E 20 404 reject H0, α = 0.1 
63 20 3071 38E 20 511   
     39E 20 897   
      36E 20 1422   
23 41 390 10C 40 45 not reject H0 
8 44 447 8C 40 123 α = 0.1/ 0.05 
71 40 674 7C 40 345   
      15C 40 624   
63 120 45 5D 120 148 not reject H0 
16 122 191 1D 120 173 α = 0.1/ 0.05 
     3D 120 359   
      13D 120 593   
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Discussion 
 
Dealing with a data set of the presented structure where individuals show a 
quite diverse behaviour with respect to the processes under investigation the 
statistical analysis should account for these individual differences by the use of 
the population approach. Since the last two decades a broad literature is 
dedicated to this problem, see for instance Racine et al. (1986) for applications 
in the pharmaceutical industry, Sheiner and Beal (1980; 1981; 1983) for the 
NONMEM approach, Steimer et al. (1984), Davidian and Giltinan (1993a,b) 
Gelman et al. (1996), Bois et al. (1996). Recently, the major focus are the 
application of MCMC methods, particularly the Gibbs sampler (Wakefield, 
1996) and physiologically based pharmacokinetic (PBPK) modelling (Bois, 
1999) – an approach that aims to model the most relevant processes with 
respect to the subject under investigation.  
Generally, a population approach should be applied in cases where individual 
differences lead to unreliable 'naïve' summary statistics even if difficulties arise 
with the estimation of the individual parameters as in the present case with the 
estimation of the AUCi. Past experience has shown that the EM estimation of 
the population mean is a minor problem even in more complex situations (cf. 
Selinski et al., 2000; Selinski, 2001).  
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Appendix 
 
Table 8: Individual AUCi after oral administration of 10 mg/kg body weight 
daidzein, with values printed bolt, if the terminal partial area under the curve 
was determined by eq. (13).  
dose, application i rat no. AUCi 
10 mg/kg, i.v. 1 8 523412 
 2 12 556765 
 3 16 848160 
 4 23 301540.48 
 5 63 630454.5 
 6 68 212740.12 
 7 69 958285 
 8 71 573855 
10 mg/kg, oral 1 4 112321 
 2 9 26368 
 3 10 13534.5 
 4 14 25239.4 
 5 15 42447 
 6 18 82529.91 
 7 19 207489.82 
 8 20 27624.5 
 9 31 35769.17 
 10 64 148986.52 
 11 70 43504.35 
 12 73 9516.57 
100 mg/kg, oral 1 21 35869.82 
 2 22 133553.18 
 3 26 201136.5 
 4 28 59290.5 
 5 29 154682.5 
 6 30 94875.13 
 7 33 72256.5 
 8 48 21652 
 9 49 9608.5 
 10 65 71670 
 11 66 246981.43 
 12 67 10038.79 
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Table 9: Individual AUCi after oral administration of 10 mg/kg body weight 
daidzein, with values printed bolt, if the terminal partial area under the curve 
was determined by eq. (13).  
dose, application i rat no. AUCi 
10 mg/kg, i.v. 1 25 364983 
 2 34 365386.21 
 3 35 370711.53 
 4 36 254084.5 
 5 42 313202.31 
 6 44 235183.5 
 7 46 286271.5 
 8 47 150710.09 
 9 55 345622.47 
10 mg/kg, oral 1 38 52756.54 
 2 39 11610 
 3 40 21033 
100 mg/kg, oral 1 50 188663.57 
 2 51 44280.00 
 3 52 65375.00 
 4 53 109391.54 
 5 54 78268.26 
 6 57 216021.39 
 7 58 102500.00 
 8 59 130462.00 
 9 60 107163.15 
 
 
Table 10. Individual AUCi after oral administration of 10 mg/kg body weight 
daidzein, with values printed bolt, if the terminal partial area under the curve 
was determined by eq. (13).  
dose, application i rat no. AUCi 
5 mg/kg, i.v. 1 4 70231.75 
 2 33 20791.43 
 3 35 117140.00 
 4 36 143213 
 5 6 51307.00 
 6 34 133596.08 
50 mg/kg, oral 1 11 188755.82 
 2 12 113551.04 
 3 13 76384.50 
 4 14 105192.86 
 5 15 39814.07 
 6 16 82422.50 
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200 mg/kg, oral 1 21 125646.27 
 2 22 462298.04 
 3 23 378220.32 
 4 24 224509.86 
 5 25 254417.00 
 6 26 211032.01 
 
 
Table 11. Daidzein 10 mg/kg, intravenous administration, non-pregnant 
DA/Han rats, AUC, 2~σ and oral bioavailability for different specifications of g. 
 g(x)= 
 
1 x 2x x² 
AUC 519927.68 506445.68 504597.57 501423.75 
2~σ  0.2100 0.1913 0.1909 0.1905 
 
Table 12. Daidzein 10 mg/kg, oral administration, non-pregnant DA/Han rats, 
AUC, 2~σ  and oral bioavailability for different specifications of g.  
 g(x)= 
 
1 x 2x x² 
AUC 43564.65 41953.80 43060.99 45442.08 
2~σ  0.3416 0.2851 0.2821 0.2798 
F  8.38% 8.28% 8.53% 9.06% 
F3-exponential  8.69% 8.37% 8.59% 9.07% 
 
Table 13. Daidzein 100 mg/kg, oral administration, non-pregnant DA/Han 
rats, AUC, 2~σ  and oral bioavailability for different specifications of g.  
 g(x)= 
 
1 x 2x x² 
AUC 61215.30 63348.00 69949.10 89884.37 
2~σ  0.5750 0.4984 0.4947 0.4916 
F  1.18% 1.25% 1.39% 1.79% 
F3-exponential  1.22% 1.26% 1.40% 1.79% 
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Table 14. Daidzein 100 mg/kg, oral administration, non-pregnant DA/Han 
rats, AUC, 2~σ  and oral bioavailability for different specifications of g, r =2, 
λ =0.8.  
 g(x)= 
 
1 x 2x x² 
AUC 60650.73 57633.34 60574.08 72938.40 
2~σ  0.2695 0.1700 0.1650 0.1609 
F  1.17% 1.14% 1.20% 1.45% 
F3-exponential  1.21% 1.15% 1.21% 1.46% 
 
Table 15. Daidzein 100 mg/kg, oral administration, non-pregnant DA/Han 
rats, AUC, 2~σ  and oral bioavailability for different specifications of g, r =0.5, 
λ =0.8.  
 g(x)= 
 
1 x 2x x² 
AUC 60650.73 57633.34 60574.08 72938.40 
2~σ  0.2695 0.1700 0.1650 0.1610 
F  1.17% 1.14% 1.20% 1.45% 
F3-exponential  1.21% 1.15% 1.21% 1.46% 
 
Table 16. Daidzein 100 mg/kg, oral administration, non-pregnant DA/Han 
rats, AUC, 2~σ  and oral bioavailability for different specifications of g, r =6, 
λ =10.  
 g(x)= 
 
1 x 2x x² 
AUC 61988.60 69572.92 78419.36 97813.86 
2~σ  1.0045 0.9572 0.9549 0.9529 
F  1.19% 1.37% 1.55% 1.95% 
F3-exponential  1.24% 1.39% 1.56% 1.95% 
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Table 17. Daidzein 100 mg/kg, oral administration, non-pregnant DA/Han 
rats, AUC, 2~σ  and oral bioavailability for different specifications of g, 
r = λ =1.  
 g(x)= 
 
1 x 2x x² 
AUC 60672.89 58036.35 61307.04 74861.06 
2~σ  0.2813 0.1909 0.1863 0.1827 
F  1.17% 1.15% 1.21% 1.49% 
F3-exponential  1.21% 1.16% 1.22% 1.49% 
 
 
Table 18. Bisphenol A 10 mg/kg, oral administration, non-pregnant DA/Han 
rats, AUC, 2~σ  and oral bioavailability for different specifications of g.  
 
 
 
 
Table 19. Bisphenol A 100 mg/kg, oral administration, non-pregnant DA/Han 
rats, AUC, 2~σ  and oral bioavailability for different specifications of g.  
 
 
 
 
 
 
 
 
 g(x)= 
 
1 x 2x x² 
AUC 40060.49 114934.68 141213.86 173923.49 
2~σ  7.3375 7.1449 7.0898 7.0217 
F3-exponential  3.55% 10.19% 12.52% 15.41% 
 g(x)= 
 
1 x 2x x² 
AUC 109675.34 160631.78 210849.99 430303.18 
2~σ  1.0277 1.0044 1.0039 1.0021 
F3-exponential  0.97% 1.42% 1.87% 3.81% 
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Table 20. p-tert-Octylphenol 50 mg/kg, oral administration, non-pregnant 
DA/Han rats, AUC, 2~σ and oral bioavailability for different specifications of g.  
 
 
 
 
 
 
 
 
Table 21. p-tert-Octylphenol 200 mg/kg, oral administration, non-pregnant 
DA/Han rats, AUC, 2~σ and oral bioavailability for different specifications of g.  
 
 
 
 
 
 
 
 g(x)= 
 
1 x 2x x² 
AUC 96583.88 125733.89 139194.98 160625.32 
2~σ  0.4694 0.4476 0.4464 0.4449 
F3-exponential  7.07% 9.20% 10.19% 11.75% 
 g(x)= 
 
1 x 2x x² 
AUC 270286.92 358344.02 392880.33 444345.49 
2~σ  0.4646 0.4471 0.4461 0.4448 
F3-exponential  4.94% 6.56% 7.19% 8.13% 
